ArticleStem cells (Dayton, Ohio)2008
Regulatory issues for personalized pluripotent cells.
Article in Stem cells (Dayton, Ohio), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 60 citations in OpenAlex.
- Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.Cell stem cell · 2024Article
- Article
- Signaling Pathways in Trans-differentiation of Mesenchymal Stem Cells: Recent Advances.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Merits and challenges of iPSC-derived organoids for clinical applications.Frontiers in cell and developmental biology · 2023Review
- hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.Journal of cellular and molecular medicine · 2016Review
- Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.Advanced drug delivery reviews · 2016Review
- Nanotopographical Surfaces for Stem Cell Fate Control: Engineering Mechanobiology from the Bottom.Nano today · 2014Article
- Induction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions.Cell stress & chaperones · 2014Article
- Embryonic and induced pluripotent stem cells: understanding, creating, and exploiting the nano-niche for regenerative medicine.ACS nano · 2013Review
- Stem cell policy exceptionalism: proceed with caution.Stem cell reviews and reports · 2012Article
- Personalized cardiac regeneration by stem cells-Hype or hope?The EPMA journal · 2011Article
- Systems biology discoveries using non-human primate pluripotent stem and germ cells: novel gene and genomic imprinting interactions as well as unique expression patterns.Stem cell research & therapy · 2010Review
- Alternative sources of pluripotent stem cells: ethical and scientific issues revisited.Stem cells and development · 2010Review
- Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?Current pharmacogenomics and personalized medicine · 2010Article
- Current protocols in the generation of pluripotent stem cells: theoretical, methodological and clinical considerations.Stem cells and cloning : advances and applications · 2009Review
- The immune boundaries for stem cell based therapies: problems and prospective solutions.Journal of cellular and molecular medicine · 2009Review
- Musings on genome medicine: is there hope for ethical and safe stem cell therapeutics?Genome medicine · 2009Article
- Developing safe therapies from human pluripotent stem cells.Nature biotechnology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The development of personalized pluripotent stem cells for research and for possible therapies holds out great hope for patients. However, such cells will face significant technical and regulatory challenges before they can be used as therapeutic reagents. Here we consider two possible sources of personalized pluripotent stem cells: embryonic stem cells derived from nuclear transfer (NT-ESCs) and induced pluripotent stem cells (iPSCs) derived from direct reprogramming of adult somatic cells. Both sources of personalized pluripotent stem cells face unique regulatory hurdles that are in some ways significantly higher than those facing stem cells derived from embryos produced by fertilization (ESCs). However, the outstanding long-term potential of iPSCs and their relative freedom from the ethical concerns raised by both ESCs and NT-ESCs makes direct reprogramming an exceptionally promising approach to advancing research and providing therapies in the field of regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.